We're off to the races!

HFA Launches 2022 Educational Series with Presentation on Joint Replacements for Patients with Bleeding Disorders

WASHINGTON, DC, December 20, 2021 – The Hemophilia Federation of America (HFA) offers monthly educational webinars for patients, caregivers and healthcare providers and is launching their 2022 series on January 18 at 7:00 pm ET with Dr. James Luck, Jr., Director of Surgical Services at the Orthopaedic Institute for Children at UCLA Health. Dr. Luck will discuss joint […]

Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal range with relatively low vector doses B-LIEVE trial to confirm dose and immune management for planned Phase 3 pivotal trial launched one quarter ahead of latest guidance LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics […]

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE)–Pfizer Inc. and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A, are being […]